Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Sartorius AG    SRT   DE0007165607

SARTORIUS AG

(SRT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sartorius : Partners With RoosterBio to Advance Cell and Gene Therapy Manufacturing

01/15/2021 | 08:52am EST
Sartorius Partners With RoosterBio to Advance Cell and Gene Therapy Manufacturing

Göttingen, January 15, 2021

The life science company Sartorius signed a strategic collaboration with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks, highly engineered media and hMSC bioprocess systems. The collaboration aims to advance the scale-up of hMSC manufacturing for regenerative medicine by leveraging the best-in-class solutions of both companies to significantly reduce process development efforts, industrialize the supply chain and accelerate the development and commercialization of groundbreaking cell-based regenerative cures.

RoosterBio and Sartorius will create a set of GMP-compatible, customer-centric protocols using RoosterBio's hMSC and media systems, alongside Sartorius's single use manufacturing technologies, process control software and cell analysis tools of hMSC final product manufacturing. Cell expansion will be rapidly optimized using Sartorius's benchtop Ambr® system and MODDE® design of experiment software allowing the technical team to compare cultures in identically sized, multi-parallel bioreactors to gain process information and optimized conditions in a short timeline. Sartorius's scalable Biostat STR® production bioreactors will then be used to scale up to 50L as part of this collaboration, with the system benefitting from scalability to 2000L. Sartorius equipment will also be leveraged to develop post-harvest processing methods with the kSep® system as well as process and quality analytics. This joint effort will simplify multiple steps in therapeutic development by providing robust, streamlined, end-to-end platform technologies and protocols that can be implemented for rapid scale up of manufacturing processes, allowing product developers to significantly speed up their development timelines.

'Taking hMSC manufacturing to the thousand-liter scale is critical in meeting product dose requirements in commercial manufacturing,' said RoosterBio CEO Margot Connor. 'For truly robust and standardized production in the field, a highly controlled manufacturing strategy is needed, with the implementation of automation, process monitoring and control to increase batch scale, consistency and efficiency. This collaboration is well-positioned to accomplish the clinical scale requirements of regenerative medicine product developers while laying foundation for true commercial scale manufacturing.'

'With the combination of technologies and tools of RoosterBio and Sartorius we support our customers to develop stem cell and therapies faster, better and more cost- efficient. Scalability is key in commercial manufacturing and this cooperation will help to meet the requirements of our customers even better', said Hugo de Wit, Head of Advanced Therapies at Sartorius.

Both companies aim to use the data from this collaboration to provide co-learning and development opportunities to support the growing cell and gene therapy industry.

Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn.

January 15, 2021
Sartorius partners with RoosterBio to advance cell and gene therapy manufacturing
PDF50.2 KB

Disclaimer

Sartorius AG published this content on 15 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 January 2021 13:51:02 UTC


© Publicnow 2021
All news about SARTORIUS AG
02/18SARTORIUS  : Conference Call FY|2020 Presentation
PU
02/18SARTORIUS STEDIM BIOTECH SA  : Communiqué de mise à disposition de documents
DJ
02/15DGAP-AFR  : Sartorius AG: Preliminary announcement of the publication of financi..
DJ
02/15SARTORIUS AG : Preliminary announcement of the publication of financial reports ..
EQ
02/11SARTORIUS  : Resolutions of the Supervisory Board of Sartorius AG
PU
02/10SARTORIUS VORZUEGE  : DZ Bank gives a Sell rating
MD
02/09SARTORIUS  : SIMCA® 17 Now Available with Improved Spectroscopy Modeling for PAT
PU
02/05SARTORIUS  : Polytec jumpstarts collaboration with Sartorius Data Analytics AB
PU
02/04SARTORIUS VORZUEGE  : UBS reiterates its Sell rating
MD
02/03SARTORIUS STEDIM BIOTECH SA  : Declaration relative to the number of shares and ..
DJ
More news
Financials
Sales 2021 2 878 M 3 456 M 3 456 M
Net income 2021 353 M 424 M 424 M
Net Debt 2021 1 814 M 2 177 M 2 177 M
P/E ratio 2021 84,6x
Yield 2021 0,28%
Capitalization 28 200 M 34 005 M 33 856 M
EV / Sales 2021 10,4x
EV / Sales 2022 9,25x
Nbr of Employees 10 637
Free-Float 46,8%
Chart SARTORIUS AG
Duration : Period :
Sartorius AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SARTORIUS AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 331,25 €
Last Close Price 395,00 €
Spread / Highest target 31,6%
Spread / Average Target -16,1%
Spread / Lowest Target -82,6%
EPS Revisions
Managers and Directors
NameTitle
Joachim Kreuzburg Chief Executive Officer
Rainer Lehmann Chief Financial Officer
Lothar Kappich Chairman-Supervisory Board
Oscar-Werner Reif Head-Research & Development
Volker Niebel Head-Production, Procurement & Business Operations
Sector and Competitors
1st jan.Capitalization (M$)
SARTORIUS AG14.49%34 005
REVENIO GROUP OYJ2.19%1 650
VAREX IMAGING CORPORATION37.47%899
CELLAVISION AB (PUBL)-4.89%827
OXFORD IMMUNOTEC GLOBAL PLC25.68%561
CO-DIAGNOSTICS, INC.47.96%389